Novel selective estrogen mimics for the treatment of tamoxifen-resistant breast cancer

Molecular Cancer Therapeutics

Volumn 13, Issue 11, 2014, Pages 2515-2526

  Molloy, Mary Ellen ^a   White, Bethany E Perez ^a,c   Gherezghiher, Teshome ^a   Michalsen, Bradley T ^a   Xiong, Rui ^a   Patel, Hitisha ^a   Zhao, Huiping ^a   Maximov, Philipp Y ^b   Jordan, V Craig ^b   Thatcher, Gregory R J ^a   Tonetti, Debra A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOTHIOPHENE; ESTROGEN; ESTROGEN RECEPTOR; TAMOXIFEN; THIOPHENE DERIVATIVE;

ANIMAL; APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; CHEMISTRY; DISEASE COURSE; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENETIC TRANSFECTION; HUMAN; MCF 7 CELL LINE; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; RANDOMIZATION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; ESTROGENS; FEMALE; HUMANS; MCF-7 CELLS; MICE; MICE, NUDE; RANDOM ALLOCATION; RECEPTORS, ESTROGEN; TAMOXIFEN; THIOPHENES; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84918799425     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0319     Document Type: Article

References (48)

1. Dempsey EC, Newton AC, Mochly-Rosen D, Fields A.P., Reyland ME, Insel PA, et al. Protein kinase C isozymes and the regulation of diverse cell responses. Am J Physiol Lung Cell Mol Physiol 2000; 279:L429-38.
2. Mackay HJ, Twelves CJ. Protein kinase C: a target for anticancer drugs? Endocr Relat Cancer 2003; 10:389-96.
3. Assender JW, Gee JMW, Lewis I, Ellis I.O., Robertson JFR, Nicholson RI. Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer. J Clin Pathol 2007; 60:1216-21.
4. Tonetti DA, Morrow M, Kidwai N., Gupta A, Badve S. Elevated protein kinase C alpha expression may be predictive of tamoxifen treatment failure. Br J Cancer 2003; 88:1400-2.
5. Lonne G, Cornmark L, Zahirovic I., Landberg G, Jirstrom K, Larsson C. PKCalpha expression is a marker for breast cancer aggressiveness. Mol Cancer 2010; 9:76.
6. Tonetti DA, Chisamore MJ, Grdina W, Schurz H., Jordan VC. Stable transfection of protein kinase C alpha cDNA in hormonedependent breast cancer cell lines. Br J Cancer 2000; 83:782-91.
7. Chisamore MJ, Ahmed Y, Bentrem D.J., Jordan VC, Tonetti DA. Novel antitumor effect of estradiol in athymic ice injected with a T47D breast cancer cell line overexpressing protein kinase C alpha. Clin Cancer Res 2001; 7:3156-65.
8. Yao K, Lee E-S, Bentrem DJ, England G, Schafer JIM, ORegan RM, et al. Antitumor action of physiological estradiol on tamoxifenstimulated breast tumors grown in athymic mice. Clin Cancer Res 2000; 6: 2028-36.
9. Ingle JN, Ahmann DL, Green S.J., Edmonson JH, Bisel HF, Kvols LK, et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 1981; 304:16-21.
10. Cole M, Jones C, Todd I. A new antioestrogenic agent in late breast cancer: an early clinical appraisal of ICI46474. Br J Cancer 1971; 25:270.
11. Perez White B, Molloy M, Zhao H., Zhang Y, Tonetti D. Extranuclear ERalpha is associated with regression of T47D PKCalphaoverexpressing, tamoxifenresistant breast cancer. Mol Cancer 2013; 12:34.
12. Lewis JS, Osipo C, Meeke K., Jordan VC. Estrogeninduced apoptosis in a breast cancer model resistant to longterm estrogen withdrawal. J Steroid Biochem Mol Biol 2005; 94:131-41.
13. Abdelhamid R, Luo J, Vandevrede L., Kundu I, Michalsen B, Litosh V.A., et al. Benzothiophene selective estrogen receptor modulators provide neuroprotection by a novel GPR30-dependent mechanism. ACS Chem Neurosci 2011; 2:256-68.
14. Catherino WH, Jordan VC. Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analogue. Cancer Lett 1995; 92:39-47.
15. O'Regan RM, Cisneros A, MacGregor J.L., Muenzner HD, Assikis VJ, Piette M, et al. Effects of the antiestrogens tamoxifen, toremifene, and ICI 182, 780 on endometrial cancer growth. J Natl Cancer Inst 1998; 90:1552-8.
16. Lin X, Yu Y, Zhao H., Zhang Y, Manela J, Tonetti DA. Overexpression of PKCα is required to impart estradiol inhibition and tamoxifenresistance in a T47D human breast cancer tumor model. Carcinogenesis 2006; 27:1538-46.
17. Zhang Y, Zhao H, Asztalos S., Chisamore M, Sitabkhan Y, Tonetti DA. Estradiolinduced regression in T47D:A18/PKCα tumors requires the estrogen receptor and interaction with the extracellular matrix. Mol Cancer Res 2009; 7:498-510.
18. Snyder KR, Sparano N, Malinowski JM. Raloxifene hydrochloride. Am J Health Syst Pharm 2000; 57:1669-75; quiz 1676-8.
19. Hochner-Celnikier D. Pharmacokinetics of raloxifene and its clinical application. Eur J Obstet Gynecol Reprod Biol 1999; 85:23-9.
20. Palkowitz AD, Glasebrook AL, Thrasher K.J., Hauser KL, Short LL, Phillips DL, et al. Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl) ethoxy]phenoxy]-2-(4-hydroxyphenyl)]benzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator. J Med Chem 1997; 40:1407-16.
21. Suh N, Glasebrook AL, Palkowitz A.D., Bryant HU, Burris LL, Starling JJ, et al. Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. Cancer Res 2001; 61: 8412-5.
22. Burke TW, Walker CL. Arzoxifene as therapy for endometrial cancer. Gynecol Oncol 2003; 90:S40-6.
23. Buzdar A, O'Shaughnessy JA, Booser DJ, Pippen JE Jr, Jones SE, Munster PN, et al. Phase II, randomized, doubleblind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol 2003; 21:1007-14.
24. Liu H, Liu J, van Breemen RB, Thatcher GRJ, Bolton JL. Bioactivation of the selective estrogen receptor modulator desmethylated arzoxifene to quinoids: 4'-fluoro substitution prevents quinoid formation. Chem Res Toxicol 2005; 18:162-73.
25. Yu B, Dietz BM, Dunlap T, Kastrati I., Lantvit DD, Overk CR, et al. Structural modulation of reactivity/activity in design of improved benzothiophene selective estrogen receptor modulators: induction of chemopreventive mechanisms. Mol Cancer Ther 2007; 6:2418-28.
26. Overk CR, Peng KW, Asghodom R.T., Kastrati I., Lantvit DD, Qin Z, et al. Structureactivity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene. ChemMedChem 2007; 2:1520-6.
27. Qin Z, Kastrati I, Ashgodom R.T., Lantvit DD, Overk CR, Choi Y, et al. Structural modulation of oxidative metabolism in design of improved benzothiophene selective estrogen receptor modulators. Drug Metab Dispos 2009; 37:161-9.
28. Liu H, Bolton JL, Thatcher GRJ. Chemical modification modulates estrogenic activity, oxidative reactivity, and metabolic stability in 4'F-DMA, a new benzothiophene selective estrogen receptor modulator. Chem Res Toxicol 2006; 19:779-87.
29. Fisher B, Costantino JP, Redmond C.K., Fisher ER, Wickerham DL, Cronin WM, et al. Endometrial cancer in tamoxifentreated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86:527-37.
30. Grese TA, Sluka JP, Bryant H.U., Cullinan GJ, Glasebrook AL, Jones CD, et al. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci U S A 1997; 94:14105-10.
31. Grese TA, Cho S, Finley D.R., Godfrey AG, Jones CD, Lugar CW III, et al. Structureactivity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene. J Med Chem 1997; 40:146-67.
32. Black LJ, Sato M, Rowley E.R., Magee DE, Bekele A, Williams DC, et al. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994; 93:63-9.
33. Fuchs-Young R, Glasebrook AL, Short L.L., Draper MW, Rippy MK, Cole HW, et al. Raloxifene is a tissueselective agonist/antagonist that functions through the estrogen receptor. Ann N Y Acad Sci 1995; 761:355-60.
34. Kennedy BJ. Massive estrogen administration in premenopausal women with metastatic breast cancer. Cancer 1962; 15:641-8.
35. Tran C, Ouk S, Clegg N.J., Chen Y., Watson PA, Arora V, et al. Development of a secondgeneration antiandrogen for treatment of advanced prostate cancer. Science 2009; 324:787-90.
36. Clegg NJ, Wongvipat J, Joseph J.D., Tran C., Ouk S, Dilhas A, et al. ARN-509: A novel antiandrogen for prostate cancer treatment. Cancer Res 2012; 72:1494-503.
37. Baselga J, Campone M, Piccart M., Burris HA, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormonereceptorpositive advanced breast cancer. N Engl J Med 2012; 366:520-9.
38. Ellis MJ, Gao F, Dehdashti F., Jeffe DB, Marcom PK, Carey LA, et al. Lowerdose vs highdose oral estradiol therapy of hormone receptorpositive, aromatase inhibitorresistant advanced breast cancer. JAMA 2009; 302:774-80.
39. Lønning PE, Taylor PD, Anker G, Iddon J, Wie L, Jørgensen L-M, et al. Highdose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 2001; 67:111-6.
40. Ingle J. Estrogen as therapy for breast cancer. Breast Cancer Res 2002; 4:133-6.
41. Jordan VC, Obiorah I, Fan P., Kim HR, Ariazi E, Cunliffe H, et al. The St. Gallen Prize Lecture 2011: Evolution of longterm adjuvant antihormone therapy: consequences and opportunities. The Breast 2011; 20 Suppl 3:S1-11.
42. Peethambaram PP, Ingle JN, Suman V.J., Hartmann LC, Loprinzi CL. Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res Treat 1999; 54:117-22.
43. Osipo C, Gajdos C, Cheng D., Jordan VC. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy. J Steroid Biochem Mol Biol 2005; 93:249-56.
44. Osipo C, Gajdos C, Liu H., Chen B, Jordan VC. Paradoxical action of fulvestrant in estradiolinduced regression of tamoxifenstimulated breast cancer. J Natl Cancer Inst 2003; 95:1597-608.
45. Liu H, Lee E-S, Gajdos C, Pearce S.T., Chen B., Osipo C, et al. Apoptotic action of 17β-estradiol in raloxifeneresistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst 2003; 95:1586-97.
46. Santen RJ, Song RX, Zhang Z, Yue W., Kumar R. Adaptive hypersensitivity to estrogen. Clin Cancer Res 2004; 10:337s-45s.
47. Song RX-D, Mor G., Naftolin F, McPherson RA, Song J, Zhang Z., et al. Effect of longterm estrogen deprivation on apoptotic responses of breast cancer cells to 17betaestradiol. J Natl Cancer Inst 2001; 93:1714-23.
48. Shim W-S, Conaway M., Masamura S, Yue W, Wang J-P, Kumar R, et al. Estradiol hypersensitivity and mitogenactivated protein kinase expression in longterm estrogen deprived human breast cancer cells in vivo. Endocrinology 2000; 141:396-405.